The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics is evaluating a first-line (1L) consolidation approach aimed at predicting and potentially preventing relapse in large B-cell lymphoma (LBCL) patients after frontline therapy.
The company is highlighting the ALPHA3 clinical trial, which focuses on the promise of allogeneic CAR-T cell therapy as a means of reshaping outcomes in LBCL. The study seeks to assess how early intervention post initial therapy could revolutionize patient care by reducing relapse rates, with broader implications for the future of cell therapy in hematologic malignancies.
View post on X Loading...
Allogene recently received FDA RMAT and Fast Track designations for its allogeneic CAR-T therapy cema-cel in LBCL, accelerating the company's regulatory progress. Earlier, the company launched the ALPHA3 trial to evaluate a consolidation strategy designed to reduce relapse rates in LBCL patients after frontline therapy. These developments mark key steps in Allogene's clinical advancement of cell therapy approaches for hematologic malignancies.